Paving the way for anti-Abeta active immunotherapy
European Pharmaceutical Review
SEPTEMBER 22, 2023
Active immunotherapy through vaccination has a far lower cost than mAb-based therapies, representing an important decrease of economic burden for healthcare systems at a global scale. 7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile.
Let's personalize your content